There are no reports of adjuvant treatments for early breast cancer causing hearing loss. Yet in this exploratory study 14/16 women who had received Fluorouracil, Epirubicin and Cyclophosphamide (FEC) chemotherapy regimen, 11 of whom also received endocrine treatment, had reduced hearing sensitivity, with 9/16 being atypical. It is not clear whether this finding is related to oestrogen reduction and/or ototoxicity but a more detailed investigation in this area is warranted given the large number of women with breast cancer who receive adjuvant treatments. © 2005 Elsevier Ltd. All rights reserved.
Jenkins, V., Beveridge, H., Low, R., & Mitra, S. (2006). Atypical hearing loss in women with breast cancer receiving adjuvant treatment. Breast, 15(3), 447–450. https://doi.org/10.1016/j.breast.2005.06.005